Beranda › Tumor Stromal Gastrointestinal › Maryland
Uji klinis Tumor Stromal Gastrointestinal di Maryland
6 studi untuk Tumor Stromal Gastrointestinal mencari peserta di lokasi di Maryland.
Kota di Maryland
Teks studi resmi (Bahasa Inggris)
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Baltimore
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07218926A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
- GSK Investigational Site, Bethesda
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07585266Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
- National Institutes of Health Clinical Center, Bethesda
Menerima pesertaStudi observasional
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04557969A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- The John Hopkins Hospital, Baltimore
- Maryland Oncology Hematology- Columbia, Rockville
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Johns Hopkins University, Baltimore
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT06655246Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.